INCY Stock Forecast 2025-2026
Distance to INCY Price Targets
INCY Price Momentum
10 Quality Stocks Worth Considering Now
Researching Incyte (INCY) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on INCY and similar high-potential opportunities.
Latest INCY Stock Price Targets & Analyst Predictions
Based on our analysis of 34 Wall Street analysts, INCY has a neutral consensus with a median price target of $73.00 (ranging from $52.00 to $92.00). The overall analyst rating is Buy (7.3/10). Currently trading at $60.68, the median forecast implies a 20.3% upside. This outlook is supported by 10 Buy, 16 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Michael Schmidt at Guggenheim, projecting a 51.6% upside. Conversely, the most conservative target is provided by Evan Seigerman at BMO Capital, suggesting a 14.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INCY Analyst Ratings
INCY Price Target Range
Latest INCY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INCY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 24, 2025 | Morgan Stanley | Vikram Purohit | Equal-Weight | Maintains | $65.00 |
| Mar 18, 2025 | Guggenheim | Michael Schmidt | Neutral | Downgrade | $92.00 |
| Mar 18, 2025 | Truist Securities | Srikripa Devarakonda | Hold | Maintains | $72.00 |
| Mar 18, 2025 | William Blair | Y Katherine Xu | Market Perform | Downgrade | $0.00 |
| Mar 11, 2025 | Citizens Capital Markets | Reni Benjamin | Market Perform | Reiterates | $0.00 |
| Feb 11, 2025 | JMP Securities | Reni Benjamin | Market Perform | Reiterates | $0.00 |
| Feb 11, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $68.00 |
| Feb 11, 2025 | Citigroup | David Lebowitz | Buy | Maintains | $88.00 |
| Feb 10, 2025 | Stifel | Stephen Willey | Hold | Maintains | $77.00 |
| Jan 23, 2025 | RBC Capital | Leonid Timashev | Sector Perform | Reiterates | $70.00 |
| Jan 14, 2025 | JMP Securities | Reni Benjamin | Market Perform | Reiterates | $0.00 |
| Jan 10, 2025 | Cantor Fitzgerald | Eric Schmidt | Neutral | Reiterates | $0.00 |
| Dec 19, 2024 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $70.00 |
| Dec 17, 2024 | UBS | Nicholas Holowko | Neutral | Assumes | $77.00 |
| Nov 19, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $74.00 |
| Nov 19, 2024 | Cantor Fitzgerald | Eric Schmidt | Neutral | Reiterates | $0.00 |
| Nov 14, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $80.00 |
| Oct 30, 2024 | BMO Capital | Evan Seigerman | Underperform | Reiterates | $52.00 |
| Oct 30, 2024 | Morgan Stanley | Vikram Purohit | Equal-Weight | Maintains | $69.00 |
| Oct 30, 2024 | B of A Securities | Tazeen Ahmad | Buy | Upgrade | $90.00 |
Incyte Corporation (INCY) Competitors
The following stocks are similar to Incyte based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Incyte Corporation (INCY) Financial Data
Incyte Corporation has a market capitalization of $11.86B with a P/E ratio of 408.4x. The company generates $4.24B in trailing twelve-month revenue with a 0.8% profit margin.
Revenue growth is +16.3% quarter-over-quarter, while maintaining an operating margin of +25.3% and return on equity of +0.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Incyte Corporation (INCY) Business Model
About Incyte Corporation
Biopharmaceutical company focused on innovative therapeutics.
Incyte Corporation generates revenue through the discovery, development, and commercialization of proprietary therapeutics, particularly in oncology and inflammation. The company profits from its flagship product aimed at treating blood cancers and continues to invest in R&D to expand its pipeline of next-generation treatments, often collaborating with other pharmaceutical companies to enhance market reach.
Headquartered in Wilmington, Delaware, Incyte is a significant player in the biopharmaceutical sector, dedicated to addressing unmet medical needs and advancing patient care through innovative solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
2,617
CEO
Mr. Herve Hoppenot
Country
United States
IPO Year
1993
Website
www.incyte.comIncyte Corporation (INCY) Latest News & Analysis
Why Incyte Stock Was Tanking This Week
6 days agoIncyte's stock fell nearly 11% this week due to disappointing results from a clinical trial for an investigative medicine.
Negative clinical trial results can signal potential setbacks for a biotech company's future revenue, prompting investors to reassess the stock's value and risk, leading to price declines.
Incyte reported that its experimental drug successfully met the primary endpoint in two late-stage trials for treating hidradenitis suppurativa.
Incyte's drug success in late-stage studies boosts its market potential, signaling a likely approval and potential revenue growth, impacting stock performance positively.
Incyte (INCY) shares dropped nearly 10% on Monday, becoming the largest decliner in the S&P 500 following its latest clinical trial results.
Incyte's significant share decline indicates negative market sentiment following disappointing clinical trial results, potentially impacting investor confidence and future stock performance.
Incyte's stock fell 13% after an analyst deemed its skin disease treatment viable but not competitive with biologics, impacting investor sentiment.
Incyte's stock drop reflects concerns over its new treatment's competitiveness, potentially impacting future revenue and market positioning, which is crucial for investor sentiment.
Incyte Corp (NASDAQ: INCY) shares fell 11.4% to $60.16 after phase three trial results indicated its skin disease treatment was effective in only half of participants.
Incyte's stock drop reflects concerns over its drug's efficacy, potentially impacting future sales and market perception, leading to decreased investor confidence and valuation.
Incyte Corporation announced topline results from its Phase 3 STOP-HS trial for povorcitinib, a JAK1 inhibitor, in adults with moderate to severe hidradenitis suppurativa.
Incyte's positive Phase 3 trial results for povorcitinib could lead to FDA approval, potentially boosting revenue and stock value, impacting investor sentiment significantly.
Frequently Asked Questions About INCY Stock
What is Incyte Corporation's (INCY) stock forecast for 2025?
Based on our analysis of 34 Wall Street analysts, Incyte Corporation (INCY) has a median price target of $73.00. The highest price target is $92.00 and the lowest is $52.00.
Is INCY stock a good investment in 2025?
According to current analyst ratings, INCY has 10 Buy ratings, 16 Hold ratings, and 1 Sell ratings. The stock is currently trading at $60.68. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INCY stock?
Wall Street analysts predict INCY stock could reach $73.00 in the next 12 months. This represents a 20.3% increase from the current price of $60.68. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Incyte Corporation's business model?
Incyte Corporation generates revenue through the discovery, development, and commercialization of proprietary therapeutics, particularly in oncology and inflammation. The company profits from its flagship product aimed at treating blood cancers and continues to invest in R&D to expand its pipeline of next-generation treatments, often collaborating with other pharmaceutical companies to enhance market reach.
What is the highest forecasted price for INCY Incyte Corporation?
The highest price target for INCY is $92.00 from Michael Schmidt at Guggenheim, which represents a 51.6% increase from the current price of $60.68.
What is the lowest forecasted price for INCY Incyte Corporation?
The lowest price target for INCY is $52.00 from Evan Seigerman at BMO Capital, which represents a -14.3% decrease from the current price of $60.68.
What is the overall INCY consensus from analysts for Incyte Corporation?
The overall analyst consensus for INCY is neutral. Out of 34 Wall Street analysts, 10 rate it as Buy, 16 as Hold, and 1 as Sell, with a median price target of $73.00.
How accurate are INCY stock price projections?
Stock price projections, including those for Incyte Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
